420 related articles for article (PubMed ID: 17194061)
1. Oral antibiotic treatment for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: review of the literature.
Khawcharoenporn T; Alan T
Hawaii Med J; 2006 Oct; 65(10):290-3. PubMed ID: 17194061
[TBL] [Abstract][Full Text] [Related]
2. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Lawrence KR; Golik MV; Davidson L
Am J Ther; 2009; 16(4):333-8. PubMed ID: 19617720
[TBL] [Abstract][Full Text] [Related]
3. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic options for treating community-acquired MRSA.
Powell JP; Wenzel RP
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
6. Analysis of empiric antimicrobial strategies for cellulitis in the era of methicillin-resistant Staphylococcus aureus.
Phillips S; MacDougall C; Holdford DA
Ann Pharmacother; 2007 Jan; 41(1):13-20. PubMed ID: 17200425
[TBL] [Abstract][Full Text] [Related]
7. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
8. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.
Szumowski JD; Cohen DE; Kanaya F; Mayer KH
Antimicrob Agents Chemother; 2007 Feb; 51(2):423-8. PubMed ID: 17116664
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
10. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome.
Ruhe JJ; Smith N; Bradsher RW; Menon A
Clin Infect Dis; 2007 Mar; 44(6):777-84. PubMed ID: 17304447
[TBL] [Abstract][Full Text] [Related]
11. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue.
Roberts S; Chambers S
Intern Med J; 2005 Dec; 35 Suppl 2():S97-105. PubMed ID: 16271065
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and therapeutic evaluation of community-acquired methicillin-resistant Staphylococcus Aureus (MRSA) skin and soft tissue infections in the emergency department.
Walraven CJ; Lingenfelter E; Rollo J; Madsen T; Alexander DP
J Emerg Med; 2012 Apr; 42(4):392-9. PubMed ID: 21524884
[TBL] [Abstract][Full Text] [Related]
14. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
Grim SA; Rapp RP; Martin CA; Evans ME
Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
[TBL] [Abstract][Full Text] [Related]
15. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.
Pallin DJ; Egan DJ; Pelletier AJ; Espinola JA; Hooper DC; Camargo CA
Ann Emerg Med; 2008 Mar; 51(3):291-8. PubMed ID: 18222564
[TBL] [Abstract][Full Text] [Related]
16. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of purulence in methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Crawford SE; David MZ; Glikman D; King KJ; Boyle-Vavra S; Daum RS
J Am Board Fam Med; 2009; 22(6):647-54. PubMed ID: 19897693
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus.
Kaka AS; Rueda AM; Shelburne SA; Hulten K; Hamill RJ; Musher DM
J Antimicrob Chemother; 2006 Sep; 58(3):680-3. PubMed ID: 16840428
[TBL] [Abstract][Full Text] [Related]
20. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
